A SEER-Medicare Analysis of Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agent

被引:0
|
作者
Stein, Eytan [1 ]
Latremouille-Viau, Dominick [2 ]
Shi, Sherry [2 ]
Guerin, Annie [2 ]
Wu, Eric [3 ]
Bonifacio, Gaetano [4 ]
Cao, Xiting [2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Anal Grp Inc, Montreal, PQ, Canada
[3] Anal Grp Inc, Boston, MA USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
来源
关键词
myelodysplastic syndromes; hypomethylating agents; real-world; MDS;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MDS-112
引用
收藏
页码:S314 / S315
页数:2
相关论文
共 50 条
  • [1] Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
    Stein, Eytan M.
    Bonifacio, Gaetano
    Latremouille-Viau, Dominick
    Shi, Sherry
    Guerin, Annie
    Wu, Eric Q.
    Sadek, Islam
    Cao, Xiting
    [J]. LEUKEMIA & LYMPHOMA, 2021, 62 (06) : 1411 - 1421
  • [2] Treatment Patterns and Outcomes in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
    Stein, Eytan M.
    Latremouille-Viau, Dominick
    Joseph, George J.
    Shi, Sherry
    Guerin, Annie
    Wu, Eric Q.
    Bonifacio, Gaetano
    Cao, Xiting
    [J]. BLOOD, 2019, 134
  • [3] Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis
    Stein, Eytan M.
    Bonifacio, Gaetano
    Latremouille-Viau, Dominick
    Shi, Sherry
    Guerin, Annie
    Wu, Eric Q.
    Sadek, Islam
    Cao, Xiting
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 234 - 243
  • [4] Healthcare Resource Utilization and Costs in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents: A SEER-Medicare Analysis
    Stein, Eytan
    Latremouille-Viau, Dominick
    Shi, Sherry
    Guerin, Annie
    Wu, Eric
    Bonifacio, Gaetano
    Cao, Xiting
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S314 - S314
  • [5] HEALTHCARE RESOURCE UTILIZATION AND COSTS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES TREATED WITH HYPOMETHYLATING AGENTS: A SEER-MEDICARE ANALYSIS
    Stein, E. M.
    Latremouille-Viau, D.
    Shi, S.
    Guerin, A.
    Wu, E.
    Bonifacio, G.
    Cao, X.
    [J]. VALUE IN HEALTH, 2020, 23 : S132 - S133
  • [6] Treatment Patterns and Economic Burden Among Elderly Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents: A SEER-Medicare Analysis
    Brunner, Andrew M.
    Huggar, David
    Copher, Ronda
    Zhou, Zheng-Yi
    Zichlin, Miriam L.
    Anderson, Annika
    Downes, Nathaniel
    McBride, Ali
    [J]. BLOOD, 2021, 138
  • [7] A SEER-MEDICARE DATA ANALYSIS OF ELDERLY GLIOBLASTOMA PATIENTS: TREATMENT PATTERNS, OUTCOMES AND COST
    Burton, Eric
    Ugiliweneza, Beatrice
    Woo, Shiao
    Skirboll, Stephen
    Boakye, Maxwell
    [J]. NEURO-ONCOLOGY, 2014, 16
  • [8] Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis
    Diego Adrianzen Herrera
    Kith Pradhan
    Rose Snyder
    Siddharth Karanth
    Murali Janakiram
    Ioannis Mantzaris
    Ira Braunschweig
    Anjali Budhathoki
    Urvi A. Shah
    Amit K. Verma
    Santosh B. Murthy
    Aditi Shastri
    [J]. Leukemia, 2020, 34 : 1689 - 1693
  • [9] Myelodysplastic syndromes and the risk of cardiovascular disease in older adults: A SEER-medicare analysis
    Herrera, Diego Adrianzen
    Pradhan, Kith
    Snyder, Rose
    Karanth, Siddharth
    Janakiram, Murali
    Mantzaris, Ioannis
    Braunschweig, Ira
    Budhathoki, Anjali
    Shah, Urvi A.
    Verma, Amit K.
    Murthy, Santosh B.
    Shastri, Aditi
    [J]. LEUKEMIA, 2020, 34 (06) : 1689 - 1693
  • [10] Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis
    Ailawadhi, Sikander
    Parikh, Kejal
    Abouzaid, Safiya
    Zhou, Zhou
    Tang, Wenxi
    Clancy, Zoe
    Cheung, Claudia
    Zhou, Zheng-Yi
    Xie, Jipan
    [J]. BLOOD ADVANCES, 2019, 3 (20) : 2986 - 2994